|
1
|
Novac N: Challenges and opportunities of
drug repositioning. Trends Pharmacol Sci. 34:267–272. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ashburn TT and Thor KB: Drug
repositioning: Identifying and developing new uses for existing
drugs. Nat Rev Drug Discov. 3:673–683. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shen YY, Yuan Y, Du YY and Pan YY:
Molecular mechanism underlying the anticancer effect of simvastatin
on MDA-MB-231 human breast cancer cells. Mol Med Rep. 12:623–630.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hoque A, Chen H and Xu XC: Statin induces
apoptosis and cell growth arrest in prostate cancer cells. Cancer
Epidemiol Biomarkers Prev. 17:88–94. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hindler K, Cleeland CS, Rivera E and
Collard CD: The role of statins in cancer therapy. Oncologist.
11:306–315. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Spampanato C, De Maria S, Sarnataro M,
Giordano E, Zanfardino M, Baiano S, Cartenì M and Morelli F:
Simvastatin inhibits cancer cell growth by inducing apoptosis
correlated to activation of Bax and down-regulation of BCL-2 gene
expression. Int J Oncol. 40:935–941. 2012. View Article : Google Scholar
|
|
7
|
Relja B, Meder F, Wilhelm K, Henrich D,
Marzi I and Lehnert M: Simvastatin inhibits cell growth and induces
apoptosis and G0/G1 cell cycle arrest in hepatic cancer cells. Int
J Mol Med. 26:735–741. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Huang X, Ma J, Xu J, Su Q and Zhao J:
Simvastatin induces growth inhibition and apoptosis in HepG2 and
Huh7 hepatocellular carcinoma cells via upregulation of Notch1
expression. Mol Med Rep. 11:2334–2340. 2015. View Article : Google Scholar
|
|
9
|
Fang Z, Tang Y, Fang J, Zhou Z, Xing Z,
Guo Z, Guo X, Wang W, Jiao W, Xu Z, et al: Simvastatin inhibits
renal cancer cell growth and metastasis via AKT/mTOR, ERK and
JAK2/STAT3 pathway. PLoS One. 8:e628232013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang T, Seah S, Loh X, Chan CW, Hartman M,
Goh BC and Lee SC: Simvastatin-induced breast cancer cell death and
deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by
metabolic products of the mevalonate pathway. Oncotarget.
7:2532–2544. 2016. View Article : Google Scholar :
|
|
11
|
Lim T, Lee I, Kim J and Kang WK:
Synergistic effect of simvastatin plus radiation in gastric cancer
and colorectal cancer: Implications of BIRC5 and connective tissue
growth factor. Int J Radiat Oncol Biol Phys. 93:316–325. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang Y, Xu SL, Wu YZ, Zhao MS, Xu WJ, Yang
HY and Li YX: Simvastatin induces caspase-dependent apoptosis and
activates P53 in OCM-1 cells. Exp Eye Res. 113:128–134. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Koyuturk M, Ersoz M and Altiok N:
Simvastatin induces apoptosis in human breast cancer cells: p53 and
estrogen receptor independent pathway requiring signalling through
JNK. Cancer Lett. 250:220–228. 2007. View Article : Google Scholar
|
|
14
|
Kumar S: Second malignant neoplasms
following radiotherapy. Int J Environ Res Public Health.
9:4744–4759. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Klein HL: The consequences of Rad51
overexpression for normal and tumor cells. DNA Repair (Amst).
7:686–693. 2008. View Article : Google Scholar
|
|
16
|
Rohwer N and Cramer T: Hypoxia-mediated
drug resistance: Novel insights on the functional interaction of
HIFs and cell death pathways. Drug Resist Updat. 14:191–201. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
El-Deiry WS: The role of p53 in
chemosensitivity and radiosensitivity. Oncogene. 22:7486–7495.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Böhnke A, Westphal F, Schmidt A, El-Awady
RA and Dahm-Daphi J: Role of p53 mutations, protein function and
DNA damage for the radiosensitivity of human tumour cells. Int J
Radiat Biol. 80:53–63. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gudkov AV and Komarova EA: The role of p53
in determining sensitivity to radiotherapy. Nat Rev Cancer.
3:117–129. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Alarcon-Vargas D and Ronai Z: p53-Mdm2 -
the affair that never ends. Carcinogenesis. 23:541–547. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Meek DW: Tumour suppression by p53: A role
for the DNA damage response? Nat Rev Cancer. 9:714–723.
2009.PubMed/NCBI
|
|
22
|
Ganguli G and Wasylyk B: p53-independent
functions of MDM2. Mol Cancer Res. 1:1027–1035. 2003.
|
|
23
|
Zhang Z and Zhang R: p53-independent
activities of MDM2 and their relevance to cancer therapy. Curr
Cancer Drug Targets. 5:9–20. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rayburn E, Zhang R, He J and Wang H: MDM2
and human malignancies: Expression, clinical pathology, prognostic
markers, and implications for chemotherapy. Curr Cancer Drug
Targets. 5:27–41. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Feng FY, Zhang Y, Kothari V, Evans JR,
Jackson WC, Chen W, Johnson SB, Luczak C, Wang S and Hamstra DA:
MDM2 inhibition sensitizes prostate cancer cells to androgen
ablation and radiotherapy in a p53-dependent manner. Neoplasia.
18:213–222. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang Z, Wang H, Li M, Agrawal S, Chen X
and Zhang R: MDM2 is a negative regulator of p21WAF1/CIP1,
independent of p53. J Biol Chem. 279:16000–16006. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang Z, Wang H, Prasad G, Li M, Yu D,
Bonner JA, Agrawal S and Zhang R: Radiosensitization by antisense
anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo
human cancer models. Clin Cancer Res. 10:1263–1273. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Duong HQ, You KS, Oh S, Kwak SJ and Seong
YS: Silencing of NRF2 reduces the expression of ALDH1A1 and ALDH3A1
and sensitizes to 5-FU in pancreatic cancer cells. Antioxidants.
6:62017. View Article : Google Scholar
|
|
29
|
Liao JK: Isoprenoids as mediators of the
biological effects of statins. J Clin Invest. 110:285–288. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hwang KE, Na KS, Park DS, Choi KH, Kim BR,
Shim H, Jeong ET and Kim HR: Apoptotic induction by simvastatin in
human lung cancer A549 cells via Akt signaling dependent
down-regulation of survivin. Invest New Drugs. 29:945–952. 2011.
View Article : Google Scholar
|
|
31
|
Shi D and Gu W: Dual roles of MDM2 in the
regulation of p53: Ubiquitination dependent and ubiquitination
independent mechanisms of MDM2 repression of p53 activity. Genes
Cancer. 3:240–248. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li Q and Lozano G: Molecular pathways:
Targeting Mdm2 and Mdm4 in cancer therapy. Clin Cancer Res.
19:34–41. 2013. View Article : Google Scholar :
|
|
33
|
Chen L, Gilkes DM, Pan Y, Lane WS and Chen
J: ATM and Chk2-dependent phosphorylation of MDMX contribute to p53
activation after DNA damage. EMBO J. 24:3411–3422. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Perry ME: Mdm2 in the response to
radiation. Mol Cancer Res. 2:9–19. 2004.PubMed/NCBI
|
|
35
|
de Toledo SM, Azzam EI, Dahlberg WK,
Gooding TB and Little JB: ATM complexes with HDM2 and promotes its
rapid phosphorylation in a p53-independent manner in normal and
tumor human cells exposed to ionizing radiation. Oncogene.
19:6185–6193. 2000. View Article : Google Scholar
|
|
36
|
Perry ME: The regulation of the
p53-mediated stress response by MDM2 and MDM4. Cold Spring Harb
Perspect Biol. 2:a0009682010. View Article : Google Scholar : PubMed/NCBI
|
